The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

(2015) Libo Zhang et al.   NEOPLASIA

Small molecules and targeted therapies in distant metastatic disease

(2009) P. Hersey et al.   ANNALS OF ONCOLOGY

High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies

(2009) M. Taylor et al.   CLINICAL CANCER RESEARCH

Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib

(2009) J. Ma et al.   CLINICAL CANCER RESEARCH

Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study

(2009) Joan H. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH

Angiogenesis as a target in neuroblastoma

(2008) Jochen Rössler et al.   EUROPEAN JOURNAL OF CANCER

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

(2008) Julia L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

A Time-Response Model for Analysis of Drug Transport and Blood Flow Response during Iontophoresis of Acetylcholine and Sodium Nitroprusside

(2008) Erik Tesselaar et al.   JOURNAL OF VASCULAR RESEARCH

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium

(2008) P. Beaudry et al.   MOLECULAR CANCER THERAPEUTICS

Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease

(2008) Thomas L. Sims et al.   SURGERY